Shares of Oncobiologics Inc (NASDAQ:ONS) have been assigned a consensus broker rating score of 3.00 (Hold) from the one brokers that cover the company, Zacks Investment Research reports. One investment analyst has rated the stock with a hold recommendation. Oncobiologics’ rating score has declined by 200% in the last 90 days as a result of various analysts’ ratings changes.

Brokers have set a 12 month consensus price target of $11.00 for the company, according to Zacks. Zacks has also assigned Oncobiologics an industry rank of 196 out of 265 based on the ratings given to its competitors.

Several research analysts have recently commented on ONS shares. Barclays downgraded Oncobiologics from an “overweight” rating to an “equal weight” rating in a report on Monday, January 29th. ValuEngine upgraded Oncobiologics from a “strong sell” rating to a “sell” rating in a report on Friday, February 2nd.

In related news, CFO Lawrence A. Kenyon sold 26,165 shares of the business’s stock in a transaction dated Friday, December 22nd. The stock was sold at an average price of $1.13, for a total transaction of $29,566.45. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Pankaj Mohan sold 104,131 shares of the business’s stock in a transaction dated Tuesday, December 19th. The shares were sold at an average price of $1.15, for a total value of $119,750.65. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 284,508 shares of company stock worth $328,317. 33.50% of the stock is owned by company insiders.

An institutional investor recently raised its position in Oncobiologics stock. Sabby Management LLC boosted its holdings in shares of Oncobiologics Inc (NASDAQ:ONS) by 5.7% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,365,763 shares of the company’s stock after purchasing an additional 127,293 shares during the period. Sabby Management LLC owned about 9.59% of Oncobiologics worth $2,371,000 at the end of the most recent reporting period. 17.90% of the stock is currently owned by hedge funds and other institutional investors.

Oncobiologics (NASDAQ:ONS) traded down $0.07 on Wednesday, hitting $1.17. The stock had a trading volume of 8,621 shares, compared to its average volume of 63,922. The stock has a market capitalization of $29.17 and a P/E ratio of -0.69. The company has a debt-to-equity ratio of -0.40, a quick ratio of 0.14 and a current ratio of 0.14. Oncobiologics has a 1 year low of $0.78 and a 1 year high of $3.77.

COPYRIGHT VIOLATION NOTICE: “Zacks: Oncobiologics Inc (ONS) Given Consensus Rating of “Hold” by Brokerages” was first reported by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another domain, it was illegally copied and reposted in violation of U.S. and international copyright law. The legal version of this news story can be accessed at

Oncobiologics Company Profile

Oncobiologics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing, manufacturing and commercializing biosimilar therapeutics. It is focused on monoclonal antibodies (mAbs) in the disease areas of immunology and oncology. The Company offers BioSymphony Platform.

Get a free copy of the Zacks research report on Oncobiologics (ONS)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Oncobiologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncobiologics and related companies with's FREE daily email newsletter.